Santhera Pharmaceuticals Holding AG SPHDF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $19.79
- Day Range
- $18.30–18.30
- 52-Week Range
- $12.28–23.25
- Bid/Ask
- $22.70 / $24.75
- Shares Outstanding
- 15.32M
- Market Cap
- $260.23M
- Volume/Avg
- 171 / 870
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.97
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Santhera Pharmaceuticals Holding AG is a Swiss specialty pharmaceutical company committed to developing and commercializing medicines to meet the needs of patients living with rare and other diseases with high unmet medical needs. It is focused on the development of treatments for pulmonary and neuromuscular diseases that currently lack treatment options. The company is currently engaged in the rollout of its AGAMREE (vamorolone) medicine for the treatment of Duchenne muscular dystrophy (DMD) globally. Santhera has one operating segment, namely the development and commercialization of products for the treatment of neuromuscular diseases. Geographically, the company generates maximum revenue from Europe, and the rest from Asia and North America.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 99
- Website
- https://www.santhera.com
Valuation
|
Metric
|
SPHDF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 1.97 |
Price/Cash Flow | — |
Price/Earnings
SPHDF
Financial Strength
|
Metric
|
SPHDF
|
|---|---|
Quick Ratio | 1.10 |
Current Ratio | 1.73 |
Interest Coverage | −0.84 |
Quick Ratio
SPHDF
Profitability
|
Metric
|
SPHDF
|
|---|---|
Return on Assets (Normalized) | −17.12% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −23.11% |
Return on Assets
SPHDF
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|PZXL@?q | LOCK|b!xw^ | $128B | |||
| Moderna Inc
MRNA
| LOCK|gJ?s<?t | LOCK|?$ | $76B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|!f#yyDP | LOCK|#%V#% | $76B | |||
| argenx SE ADR
ARGX
| LOCK|&q?lM! | LOCK|?n | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|y@BKQkV | LOCK|z# | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|zdnJF!R | LOCK|&MG! | $29B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|<Gh?s^Sr | LOCK|GX!$ | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|Drr^dt@ | LOCK|&B@ | $24B | |||
| Incyte Corp
INCY
| LOCK|cjm!G^@ | LOCK|cq% | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|<mRJ#w | LOCK|?< | $15B |
United States